Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.

Hepatitis B virus (HBV) polymerase and human immunodeficiency virus (HIV) reverse transcriptase are structurally related. However, the HBV enzyme has a protein priming activity absent in the HIV enzyme. Approved nucleoside/nucleotide inhibitors of the HBV polymerase include lamivudine, adefovir, telbivudine, entecavir and tenofovir. Although most of them target DNA elongation, guanosine and adenosine analogs (e.g. entecavir and tenofovir, respectively) also impair protein priming. Major mutational patterns conferring nucleoside/nucleotide analog resistance include the combinations rtL180M/rtM204(I/V) (for lamivudine, entecavir, telbivudine and clevudine) and rtA181V/rtN236T (for adefovir and tenofovir). However, development of drug resistance is very slow for entecavir and tenofovir. Novel nucleoside/nucleotide analogs in advanced clinical trials include phosphonates similar to adefovir or tenofovir, and new tenofovir derivatives with improved pharmacological properties.

[1]  Robert A. Domaoal,et al.  Pre-steady-state Kinetic Studies Establish Entecavir 5′-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase* , 2008, Journal of Biological Chemistry.

[2]  L. Menéndez-Arias.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. , 2013, Antiviral research.

[3]  R. Schinazi,et al.  Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase* , 2008, Journal of Biological Chemistry.

[4]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[5]  K. Borroto-Esoda,et al.  Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. , 2007, Journal of hepatology.

[6]  C. Mazzucco,et al.  Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance , 2008, Hepatology.

[7]  Y. Shiratori,et al.  Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. , 1999, The Journal of clinical investigation.

[8]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[9]  S. Sarafianos,et al.  Antiviral therapies: focus on hepatitis B reverse transcriptase. , 2012, The international journal of biochemistry & cell biology.

[10]  K. Borroto-Esoda,et al.  The YMDD and rtA194T Mutations Result in Decreased Replication Capacity in Wild-Type HBV as well as in HBV with Precore and Basal Core Promoter Mutations , 2011, Antiviral chemistry & chemotherapy.

[11]  Michael D. Miller,et al.  No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B , 2014, Hepatology.

[12]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[13]  D. Loeb,et al.  The Topology of Hepatitis B Virus Pregenomic RNA Promotes Its Replication , 2007, Journal of Virology.

[14]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[15]  Le Li,et al.  The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  M. Helm,et al.  Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy , 2009, Journal of Clinical Microbiology.

[17]  J. Tavis,et al.  The Duck Hepatitis B Virus Polymerase Is Activated by Its RNA Packaging Signal, ɛ , 1998, Journal of Virology.

[18]  J. Barnard,et al.  Kinetic Analysis of Wild-Type and YMDD Mutant Hepatitis B Virus Polymerases and Effects of Deoxyribonucleotide Concentrations on Polymerase Activity , 2002, Antimicrobial Agents and Chemotherapy.

[19]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[20]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[21]  P. Colson,et al.  Unusual Selection of Rta181V Hbv Mutants Cross-Resistant to Adefovir following Prolonged Lamivudine Monotherapy: Report of Two Cases , 2005, Antiviral therapy.

[22]  H. Lee,et al.  Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[23]  S. Sarafianos,et al.  The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes , 2013, PLoS pathogens.

[24]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[25]  Huiling Yang,et al.  In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.

[26]  C. Yurdaydın,et al.  YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine , 2003, Journal of viral hepatitis.

[27]  Chang-jiang Zhang,et al.  Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. , 2014, Antiviral research.

[28]  Xiaodong Zhang,et al.  Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance , 2013, Hepatitis monthly.

[29]  R. Kaiser,et al.  Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment , 2004, AIDS (London).

[30]  F. Zoulim,et al.  Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. , 2008, Journal of hepatology.

[31]  M. Manns,et al.  In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.

[32]  M. Imamura,et al.  Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif , 2006, Antimicrobial Agents and Chemotherapy.

[33]  Y. Wen,et al.  Carbonyl J Acid Derivatives Block Protein Priming of Hepadnaviral P Protein and DNA-Dependent DNA Synthesis Activity of Hepadnaviral Nucleocapsids , 2012, Journal of Virology.

[34]  Ronald E. Rose,et al.  Inhibition of Hepatitis B Virus Polymerase by Entecavir , 2007, Journal of Virology.

[35]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[36]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[37]  W. Choe,et al.  Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B Patients , 2010, Journal of Virology.

[38]  K. Tanikawa,et al.  Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B , 2009, Hepatology international.

[39]  N. Ferguson,et al.  Large-Scale Production and Structural and Biophysical Characterizations of the Human Hepatitis B Virus Polymerase , 2013, Journal of Virology.

[40]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[41]  I Sauvaget,et al.  Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.

[42]  H. Lee,et al.  rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy , 2012, Journal of gastroenterology and hepatology.

[43]  F. Zoulim,et al.  The life cycle of hepatitis B virus and antiviral targets , 2011 .

[44]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[45]  D. Glebe,et al.  The Molecular Virology of Hepatitis B Virus , 2013, Seminars in Liver Disease.

[46]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[47]  T. Luedde,et al.  Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants , 2004, Journal of Virology.

[48]  C. Yurdaydın,et al.  Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy , 2005, Antimicrobial Agents and Chemotherapy.

[49]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[50]  F. Tacke,et al.  Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient , 2009, AIDS.

[51]  M. Manns,et al.  Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus , 2001, Antimicrobial Agents and Chemotherapy.

[52]  Scott A. Jones,et al.  Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine , 2013, Antimicrobial Agents and Chemotherapy.

[53]  David,et al.  In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2′,3′-Dideoxy-3′-Fluoroguanosine , 2006, Antimicrobial Agents and Chemotherapy.

[54]  G. Radziwill,et al.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity , 1990, Journal of virology.

[55]  M. Yuen,et al.  Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B , 2013, Gut.

[56]  Li Chen,et al.  rtM204Q May Serve as a Novel Lamivudine-Resistance-Associated Mutation of Hepatitis B Virus , 2014, PloS one.

[57]  M. Yuen,et al.  Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice , 2009, Antimicrobial Agents and Chemotherapy.

[58]  Scott A. Jones,et al.  In Vitro Epsilon RNA-Dependent Protein Priming Activity of Human Hepatitis B Virus Polymerase , 2012, Journal of Virology.

[59]  Lai Wei,et al.  rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B , 2010, Journal of viral hepatitis.

[60]  Fujun Li,et al.  Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. , 2008, Journal of pharmaceutical sciences.

[61]  R. Idilman,et al.  Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[62]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[63]  D. Hoffmann,et al.  The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. , 2013, Antiviral research.

[64]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[65]  M. Sterneck,et al.  Prevalence, Incidence, and Clinical Relevance of the Reverse Transcriptase V207I Mutation Outside the YMDD Motif of the Hepatitis B Virus Polymerase during Lamivudine Therapy , 2005, Journal of Clinical Microbiology.

[66]  Y. Karino,et al.  Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation , 2009, Antimicrobial Agents and Chemotherapy.

[67]  A. Huang,et al.  Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy , 2012, Journal of medical virology.

[68]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[69]  I. Hung,et al.  Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. , 2011, Journal of hepatology.

[70]  N. Warner,et al.  The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.

[71]  D. Vassilopoulos,et al.  The natural course of chronic hepatitis B virus infection and its management. , 2013, Advances in pharmacology.

[72]  R. Miller,et al.  Mutation rate of the hepadnavirus genome. , 1989, Virology.

[73]  Scott A. Jones,et al.  Protein-Primed Terminal Transferase Activity of Hepatitis B Virus Polymerase , 2013, Journal of Virology.

[74]  N. Warner,et al.  The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[75]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[76]  R. Siliciano,et al.  The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients , 2008, AIDS.

[77]  F. Gao,et al.  Association of Preexisting Drug-Resistance Mutations and Treatment Failure in Hepatitis B Patients , 2013, PloS one.

[78]  I. Serra,et al.  Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. , 2009, Antiviral research.

[79]  W. Choe,et al.  The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene , 2014, Journal of Virology.

[80]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[81]  C. Yurdaydın,et al.  A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment , 2007, Antiviral therapy.

[82]  M. Sede,et al.  Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. , 2012, Antiviral research.

[83]  C. Yeh,et al.  Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. , 2012, The Journal of antimicrobial chemotherapy.

[84]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[85]  M. Nassal.  Hepatitis B viruses: reverse transcription a different way. , 2008, Virus research.

[86]  J. Tavis,et al.  β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. , 2013, Antiviral research.

[87]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[88]  H. Lee,et al.  Entecavir plus Adefovir Combination Treatment for Chronic Hepatitis B Patients after Failure of Nucleoside/Nucleotide Analogues , 2012, Antiviral therapy.

[89]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[90]  B. Berkhout,et al.  Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. , 2013, The Journal of infection.

[91]  Tommy F. Liu,et al.  Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. , 2010, Antiviral research.

[92]  V. Soriano,et al.  Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. , 2008, The Journal of antimicrobial chemotherapy.

[93]  E. Elias,et al.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.